Ivermectin Orion

Ivermectin, the active ingredient in Ivermectin Orion, is an anthelmintic presented as an oral tablet for oral use. It treats a range of parasitic infections such as onchocerciasis, strongyloidiasis, scabies, lymphatic filariasis and other intestinal helminth infections.

GNH USA supplies Ivermectin Orion as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Ivermectin is an antiparasitic agent used to treat infections caused by various helminths and ectoparasites. - Onchocerciasis: reduces microfilarial load and prevents disease progression. - Strongyloidiasis: eliminates intestinal larvae and prevents hyperinfection. - Scabies: eradicates Sarcoptes mites and resolves skin lesions. - Lymphatic filariasis (as part of combination therapy): contributes to microfilariae clearance. - Other intestinal helminth infections: treats a variety of nematode infections.

Ivermectin is generally well tolerated, but adverse reactions can occur.

Common Side Effects: - Nausea - Dizziness - Diarrhea - Abdominal pain

Serious or Rare Side Effects: - Severe skin rash or Stevens‑Johnson syndrome - Hepatotoxicity - Neutropenia - Anaphylactic reactions

Before prescribing Ivermectin, clinicians should consider several safety aspects. - Contraindications: avoid in patients with known hypersensitivity to ivermectin. - Liver function: monitor hepatic enzymes in patients with pre‑existing liver disease. - Co‑infection: evaluate for loiasis before treatment in endemic areas. - Elderly patients: use with caution due to potential increased sensitivity. - Pregnancy and breastfeeding: assess risk‑benefit ratio as safety data are limited. - Store at ambient temperature: keep in the original pack, protect from moisture.

Ivermectin may interact with other medicines, requiring attention to potential effects.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole): may increase ivermectin plasma levels. - Warfarin: concurrent use may enhance anticoagulant effect and bleeding risk. - P‑glycoprotein inhibitors (e.g., verapamil): can raise systemic exposure.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampicin): may reduce ivermectin efficacy. - Other antiparasitic agents: may increase gastrointestinal adverse effects.